Published in Urology on July 13, 2011
Critical Analysis of the Use of Uroflowmetry for Urethral Stricture Disease Surveillance. Urology (2016) 1.46
Re: Seibold et al.: Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty (Urology 2011;78:696-700). Urology (2011) 0.75
The role of noninvasive testing and questionnaires in urethroplasty follow-up. Transl Androl Urol (2014) 0.75
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Urinary diversion. Urology (2007) 2.65
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Combination of lidocaine suppository and periprostatic nerve block during transrectal prostate biopsy: a prospective randomized trial. Int J Urol (2014) 1.98
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Extracellular matrix degradation and reduced neural density in children with intrinsic ureteropelvic junction obstruction. Urology (2010) 1.75
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int (2008) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67
ERG rearrangement in small cell prostatic and lung cancer. Histopathology (2010) 1.64
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51
Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47
Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Activating transcription factor 3: a hormone responsive gene in the etiology of hypospadias. Eur J Endocrinol (2008) 1.12
Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med (2013) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm (2009) 1.10
Anatomical radical retropubic prostatectomy: 'curtain dissection' of the neurovascular bundle. BJU Int (2005) 1.10
HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08
Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.07
Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys (2010) 1.07
Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol (2012) 1.04
Differentiation of urinary calculi with dual energy CT: effect of spectral shaping by high energy tin filtration. Invest Radiol (2010) 1.04
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int (2012) 1.04
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci (2009) 1.02
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res (2006) 1.02
Investigations of urothelial cells seeded on commercially available small intestine submucosa. Eur Urol (2006) 1.01
The immunology of fibrosis: innate and adaptive responses. Trends Immunol (2010) 1.01
Can we still afford bladder cancer? Curr Opin Urol (2008) 1.01
Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med (2008) 1.01